PSMA-PET based radiotherapy: a review of initial experiences, survey on current practice and future perspectives-Reference-Cited by-同舟云学术

PSMA-PET based radiotherapy: a review of initial experiences, survey on current practice and future perspectives

Published:2018-05-11 Issue:1 Volume:13 Page:
ISSN:1748-717X
Container-title:Radiation Oncology
language:en
Short-container-title:Radiat Oncol

Author:

Zschaeck Sebastian^ORCID,Lohaus Fabian,Beck Marcus,Habl Gregor,Kroeze Stephanie,Zamboglou Constantinos,Koerber Stefan Alexander,Debus Jürgen,Hölscher Tobias,Wust Peter,Ganswindt Ute,Baur Alexander D. J.,Zöphel Klaus,Cihoric Nikola,Guckenberger Matthias,Combs Stephanie E.,Grosu Anca Ligia,Ghadjar Pirus,Belka Claus

Publisher

Springer Science and Business Media LLC

Subject

Radiology, Nuclear Medicine and imaging,Oncology

Link

http://link.springer.com/content/pdf/10.1186/s13014-018-1047-5.pdf

Reference71 articles.

1. Perera M, Papa N, Christidis D, Wetherell D, Hofman MS, Murphy DG, et al. Sensitivity, specificity, and predictors of positive (68)Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate Cancer: a systematic review and meta-analysis. Eur Urol. 2016;70:926–37. https://doi.org/10.1016/j.eururo.2016.06.021 .

2. von Eyben FE, Picchio M, von Eyben R, Rhee H, Bauman G. (68)Ga-labeled prostate-specific membrane antigen ligand positron emission tomography/computed tomography for prostate Cancer: a systematic review and meta-analysis. Eur Urol Focus. 2016; https://doi.org/10.1016/j.euf.2016.11.002 .

3. Eder M, Schäfer M, Bauder-Wüst U, Hull W-E, Wängler C, Mier W, et al. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem. 2012;23:688–97. https://doi.org/10.1021/bc200279b .

4. Afshar-Oromieh A, Haberkorn U, Eder M, Eisenhut M, Zechmann CM. [68Ga]gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH. Eur J Nucl Med Mol Imaging. 2012;39:1085–6. https://doi.org/10.1007/s00259-012-2069-0 .

5. Afshar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart HG, Hadaschik BA, et al. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2013;40:486–95. https://doi.org/10.1007/s00259-012-2298-2 .

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pelvic lymph node mapping in prostate cancer: examining the impact of PSMA PET/CT on radiotherapy decision-making in patients with node-positive disease;Cancer Imaging;2024-07-29

2. The Current Landscape of Prostate-Specific Membrane Antigen (PSMA) Imaging Biomarkers for Aggressive Prostate Cancer;Cancers;2024-02-26

3. Towards simulation-free MR-linac treatment: utilizing male pelvis PSMA-PET/CT and population-based electron density assignments;Physics in Medicine & Biology;2023-09-22

4. Chancen der PSMA(prostataspezifisches Membranantigen)-Hybridbildgebung beim Prostatakarzinom;Die Urologie;2023-09-13

5. Is the Patient Actually Failing on Enzalutamide? A Case Report and Issues to Consider in Enzalutamide-Resistant Oligoprogressive Metastatic Castrate-Resistant Prostate Cancer;Reviews on Recent Clinical Trials;2023-05